New drug JNJ-89402638 enters human trials for Tough-to-Treat GI cancers

NCT ID NCT06663319

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This early-phase study is testing an experimental drug called JNJ-89402638 in people with metastatic colorectal or gastric cancer that has progressed after at least two prior treatments. The trial will first find the safest dose and schedule, then test the drug alone or combined with standard chemotherapy and/or bevacizumab. About 260 participants will be enrolled to monitor side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JNJ-89402638 (an experimental drug) given alone or with bevacizumab and/or chemotherapy (FOLFOX or FOLFIRI)
What this could lead to: If this trial succeeds, it could point toward a new treatment option for people with advanced colorectal or gastric cancer who have run out of standard therapies.
What could go wrong: This is a very early Phase 1 study focused on safety and dosing, not on proving the drug works. Many experimental cancer drugs fail in early testing, and side effects like cytokine release syndrome are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm digestive system neoplasm gastric carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL NEOPLASMS GASTROINTESTINAL NEOPLASMS UNRESECTABLE/METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Community Health Network
RECRUITING

Indianapolis, Indiana, 46256, United States
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
Hosp Univ Fund Jimenez Diaz
RECRUITING

Madrid, 28040, Spain
Hosp Univ Hm Sanchinarro
RECRUITING

Madrid, 28050, Spain
Hosp Univ Vall D Hebron
RECRUITING

Barcelona, 08035, Spain
Hosp. Univ. 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Severance Hospital Yonsei University Health System
RECRUITING

Seoul, 03722, South Korea
Start Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
Swedish Cancer Institute
RECRUITING

Seattle, Washington, 98104, United States
University of Colorado Denver Anschultz Medical Campus
RECRUITING

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.